Danaher Corp

Danaher operates diversified scientific and industrial businesses through three segments: Biotechnology (life science research tools and consumables), Life Sciences (diagnostics and clinical instruments), and Diagnostics (testing equipment and reagents). Major operating companies include Cytiva, Beckman Coulter, Cepheid, and Pall. Revenue comes from recurring consumables and services alongside capital equipment sales, with strong exposure to biopharma R&D spending and clinical diagnostics.

Danaher demonstrates consistent organic growth and margin expansion through its disciplined Danaher Business System management approach and focus on high-quality life sciences markets. The stock typically trades at premium P/E ratios reflecting reliable execution. Strengths include recurring revenue from consumables, exposure to biopharma innovation, and operational improvement culture. Risks include cyclicality in bioprocessing capital equipment, customer concentration in large pharma companies, and execution following the Cytiva acquisition. The company maintains industry-leading margins.

In life sciences tools, Thermo Fisher Scientific is the primary competitor across research instruments, consumables, and services. Agilent Technologies competes in analytical instruments and diagnostics. PerkinElmer overlaps in life sciences research. For diagnostics, Roche and Abbott compete in clinical testing. Sartorius and Merck KGaA compete in bioprocessing. GE HealthCare competes in medical diagnostics imaging. Waters and Bruker compete in specific analytical instrument categories.

Danaher pays a modest quarterly dividend with a very low payout ratio below 10% of earnings, prioritizing capital allocation toward acquisitions and organic growth investment. The company has increased its dividend annually but at slow rates compared to earnings growth, viewing M&A as the highest-return use of capital. Management follows a disciplined acquisition strategy targeting high-quality life sciences and diagnostics businesses, with dividends serving as a stable but secondary capital return mechanism.

DHR last closed at $190.10, up 0.05% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $171.00 and a high of $242.80. The current price represents 27% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 30 analysts covering DHR, the consensus rating is Strong Buy — 26 rate it a buy, 4 hold, and 0 sell. The average price target sits at $158.11, implying 17% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Danaher Corp generated $24.26B in revenue during fiscal year 2026, with $3.57B reaching the bottom line as net income. The net profit margin of 14.7% is solid for its sector.

DHR trades at a P/E ratio of 37.05 on trailing earnings of $5.05 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Life Sciences Tools & Services sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -17.46% (3M), +2.85% (6M), -10.50% (1Y), -17.49% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether DHR is outperforming or lagging the broader market.